91
Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL
Condition(s):Safety and EfficacyLast Updated:April 14, 2022Recruiting
Histone Deacetylase Inhibitors: 749 Clinical Trials, Page 10 of 75
Hide Studies Not Open or Pending
92
Azacytidine and Valproic Acid in Patients With Advanced Cancers
Condition(s):Advanced CancersLast Updated:August 1, 2012Completed
93
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Condition(s):Lymphoid Malignancies; Multiple Myeloma; Lymphoma; Hodgkin Lymphoma; Non-hodgkin LymphomaLast Updated:November 23, 2022Completed
94
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
Condition(s):Acute Myelogenous LeukemiaLast Updated:June 24, 2015Completed
95
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
Condition(s):Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Mantle Cell LymphomaLast Updated:May 20, 2014Terminated
96
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
Condition(s):LymphomaLast Updated:February 11, 2013Completed
97
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Condition(s):Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, DiffuseLast Updated:November 17, 2020Completed
98
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
Condition(s):High Grade Gliomas; Brain TumorsLast Updated:August 18, 2016Completed
99
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Condition(s):Lymphoma, T-Cell, CutaneousLast Updated:March 24, 2016Completed
100
Study of SB939 in Subjects With Myelofibrosis
Condition(s):Myeloproliferative DisordersLast Updated:January 30, 2014Completed